Edition:
United States

Novavax Inc (NVAX.O)

NVAX.O on Nasdaq

1.29USD
5 Dec 2016
Change (% chg)

$0.05 (+4.03%)
Prev Close
$1.24
Open
$1.24
Day's High
$1.29
Day's Low
$1.24
Volume
4,960,099
Avg. Vol
15,301,514
52-wk High
$8.95
52-wk Low
$1.16

NVAX.O

Chart for NVAX.O

About

Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine... (more)

Overall

Beta: 1.84
Market Cap(Mil.): $352.62
Shares Outstanding(Mil.): 271.25
Dividend: --
Yield (%): --

Financials

  NVAX.O Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -1.12 -- --
ROI: -79.00 -1.09 14.95
ROE: -144.75 -2.39 16.29

BRIEF-Novavax reports Q3 loss per share $0.24

* Q3 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S

Nov 09 2016

Novavax cuts jobs to push ahead with respiratory vaccine for elderly

Nov 9 Novavax Inc said on Wednesday it would cut 30 percent of its global workforce, or 164 jobs, to help fund the testing of its vaccine for a common respiratory virus in the elderly, about two months after failing a late-stage study.

Nov 09 2016

Novavax vaccine for respiratory disease fails in late stage trial

Novavax Inc said on Thursday that its experimental vaccine for a serious infectious respiratory disease failed at the final stage of human testing, sending its stock plunging more than 80 percent.

Sep 15 2016

BRIEF-Novavax Q2 loss per share $0.29

* Q2 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S

Aug 09 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF69.50 0.00
Merck & Co., Inc. (MRK.N) $60.25 -0.88
Sanofi SA (SASY.PA) €74.40 -1.66
GlaxoSmithKline plc (GSK.L) 1,450.00p -9.00
AstraZeneca plc (AZN.L) 4,015.33p -21.00

Earnings vs. Estimates